Влияние недавних изменений в GVP ЕАЭС
January 21, 2025
New Amendments in Federal Law “On Circulation of Medicines” in Russia
On 30 January 2024, Federal Law No. 1-FZ was adopted, introducing amendments to Law No. 61-FZ "On the Circulation of Medicines" in Russia. These changes aim to bring Russian legislation with unified requirements within the Eurasian Economic Union (EAEU) and improve existing regulatory frameworks. The Law comes into effect from the day of its official publication, except for provisions with specified timelines.
According to the new Law, the amendments address various aspects of regulation, including the protection of clinical trial data, electronic government services, registration procedures, etc.
Significant changes have also been made to the conditions for the circulation of orphan and high-tech medicines, introducing a new definition for high-tech medicinal products and these imports in foreign packages.
Some significant amendments can also be highlighted:
- Electronic Document Exchange
From 1 January 2025, government services for the circulation of medicines will be provided through electronic documents. The decision has been made to completely abandon paper-based document exchange.
- Extension of Annual Test Protocol Submission Due Dates
From 1 September 2024, the due dates for the annual submission of test protocols for one batch of medicines released to the market have been extended by 2 months. They will need to be submitted to the Regulator by 1 April.
- Simplification Procedure for Introducing New Medicines into Сirculation
From 1 September 2024, manufacturers may provide protocols only for the initial batch of medicines first produced in Russia or first imported, subject to simultaneous execution of the following conditions:
- Providing a GMP (Good Manufacturing Practice) certificate
- Absence of instances of non-compliance with established quality requirements for pharmaceuticals on all manufacturing sites of the producer in the preceding three years.
These amendments, in our view, are aimed at simplifying the registration process and reducing costs associated with bringing medicinal products to market. Despite this, numerous nuances are in the new Law that must be understood to ensure a successful registration process.
Inpharmatis specializes in the registration of medicines across the EAEU countries (Armenia, Belarus, Kazakhstan, Kyrgyzstan, Russia). The experienced local team provides professional support for medicines registration with the requirements of the Eurasian Economic Union considering all ongoing regulatory changes.
Receive a personal proposal for medicines registration or request additional information about the services, reach out to us at info@inpharmatis.com.


Impact of Recent Changes in EAEU GVP
January 21, 2025
Новые правила оплаты регистрации лекарственных средств и медицинских изделий в Узбекистане
December 03, 2024
New Payment Rules for Medicines and Medical Device Registration in Uzbekistan
December 03, 2024
Inpharmatis открыла юридическое лицо в Узбекистане
November 28, 2024
Inpharmatis Opens an LLC Legal Entity in Uzbekistan
November 28, 2024
Полина Домбуре, генеральный директор Inpharmatis Group, выступит спикером на вебинаре, организованном TOPRA
October 16, 2024
Dr. Polina Dombure to Speak at TOPRA Webinar "Navigating Regulatory Changes in Moldova and Ukraine"
October 16, 2024
Полина Домбуре, генеральный директор Inpharmatis Group, примет участие в CPHI Milan 8-10 октября 2024
September 25, 2024
Dr. Polina Dombure, CEO of Inpharmatis Group, will be attending CPHI Milan in 8-10 October 2024
September 25, 2024